Higher Order Corrections to Supersymmetric Production and Decay Processes

In the first part of this thesis the decay of the light stop into a charm quark and the lightest neutralino is calculated at one-loop level in the Minimal Supersymmetric extension of the Standard Model (MSSM) in the framework of Minimal Flavor Violation (MFV). The second part of this thesis covers the calculation of next-to-leading order (NLO) corrections in the strong coupling constant to the pair production of squarks of the first two generations in the MSSM

Squark Production and Decay matched with Parton Showers at NLO

Extending previous work on the predictions for the production of supersymmetric (SUSY) particles at the LHC, we present the fully differential calculation of the next-to-leading order (NLO) SUSY-QCD corrections to the production of squark and squark-antisquark pairs of the first two generations. The NLO cross sections are combined with the subsequent decay of the final state (anti)squarks into the lightest neutralino and (anti)quark at NLO SUSY-QCD. No assumptions on the squark masses are made, and the various subchannels are taken into account independently. In order to obtain realistic predictions for differential distributions the fixed-order calculations have to be combined with parton showers. Making use of the Powheg method we have implemented our results in the Powheg-Box framework and interfaced the NLO calculation with the parton shower Monte Carlo programs Pythia6 and Herwig++. The code is publicly available and can be downloaded from the Powheg-Box webpage. The impact of the NLO corrections on the differential distributions is studied and parton shower effects are investigated for different benchmark scenarios.Comment: 36 pages, 10 figure

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Science ouverte et montage de projets de recherche - Boîte à outils

&lt;p&gt;Implémenter une stratégie de science ouverte dans le cycle de vie d'un projet de recherche.&lt;/p&gt

Light stop decays into Wbilde3˘c710W b ilde\u3c7_1^0 near the kinematic threshold

We investigate the decays of the light stop in scenarios with the lightest neutralino $ilde{chi}_1^0$ being the lightest supersymmetric particle, including flavour-violating (FV) effects. We analyse the region where the three-body decay $ilde{t}_1 o W b ilde{chi}_1^0$ is kinematically allowed and provide a proper description of the transition region between the three-body decay and the four-body decay $ilde{t}_1 o ilde{chi}_1^0 b f ar{f}'$. The improved treatment has been implemented in the Fortran package { t SUSY-HIT} and is used for the analysis of this region. A scan over the parameter range including all relevant experimental constraints reveals that the FV two-body decay into charm and $ilde{chi}_1^0$ can be as important as the three-, respectively, four-body decays if not dominant and therefore should be taken into account in order to complete the experimental searches for the light stop

Light stop decays into Wbχ˜10 near the kinematic threshold

AbstractWe investigate the decays of the light stop in scenarios with the lightest neutralino χ˜10 being the lightest supersymmetric particle, including flavour-violating (FV) effects. We analyse the region where the three-body decay t˜1→Wbχ˜10 is kinematically allowed and provide a proper description of the transition region between the three-body decay and the four-body decay t˜1→χ˜10bff¯′. The improved treatment has been implemented in the Fortran package SUSY-HIT and is used for the analysis of this region. A scan over the parameter range including all relevant experimental constraints reveals that the FV two-body decay into charm and χ˜10 can be as important as the three-, respectively, four-body decays if not dominant and therefore should be taken into account in order to complete the experimental searches for the light stop